RA Capital Management, L.P. 13D and 13G filings for Fulcrum Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-16 8:21 pm Purchase |
2024-09-12 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 10,229,099 19.300% |
4,684,883 (+84.50%) |
Filing |
| 2024-08-23 4:16 pm Sale |
2024-08-21 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 5,544,216 9.990% |
-6,065,488 (-52.24%) |
Filing |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 11,609,704 18.800% |
1,923,076 (+19.85%) |
Filing |
| 2023-01-06 4:30 pm Purchase |
2023-01-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 9,686,628 18.600% |
2,686,628 (+38.38%) |
Filing |
| 2022-08-26 4:38 pm Purchase |
2022-08-16 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 7,000,000 13.450% |
7,000,000 (New Position) |
Filing |